- Report
- July 2023
- 256 Pages
China
From €3843EUR$4,000USD£3,299GBP
- Report
- July 2023
- 88 Pages
China
From €1730EUR$1,800USD£1,485GBP
- Report
- July 2023
- 272 Pages
China
From €3843EUR$4,000USD£3,299GBP
- Report
- October 2023
- 102 Pages
Global
From €3500EUR$3,902USD£3,110GBP
- Report
- September 2023
- 101 Pages
Global
From €3500EUR$3,902USD£3,110GBP
- Report
- July 2023
- 95 Pages
Global
From €3500EUR$3,902USD£3,110GBP
- Report
- January 2024
- 93 Pages
Global
From €3500EUR$3,902USD£3,110GBP
- Report
- August 2022
- 871 Pages
Global
From €2402EUR$2,500USD£2,062GBP
- Report
- July 2023
- 129 Pages
China
From €1730EUR$1,800USD£1,485GBP
- Report
- September 2019
Global
From €5160EUR$5,370USD£4,429GBP
Paclitaxel is a chemotherapy drug used to treat breast cancer. It is a semi-synthetic derivative of the natural product Taxol, which is extracted from the bark of the Pacific yew tree. Paclitaxel works by interfering with the normal process of cell division, preventing cancer cells from dividing and growing. It is typically used in combination with other drugs, such as doxorubicin, to treat advanced stages of breast cancer.
Paclitaxel is available in both intravenous and oral formulations, and is often used in combination with other drugs to treat metastatic breast cancer. It is also used to treat other types of cancer, such as ovarian and lung cancer.
Paclitaxel is marketed by several pharmaceutical companies, including Bristol-Myers Squibb, Pfizer, and Sanofi. It is also available as a generic drug in some countries.
Companies in the Paclitaxel market include Bristol-Myers Squibb, Pfizer, Sanofi, Mylan, Teva Pharmaceuticals, and Apotex. Show Less Read more